News-Morimatsu LifeSciences

FROM CRITICAL EQUIPMENT TO
TOTAL PROCESS SOLUTION

BACK

Morimatsu Joins BioPIPS to Build an Innovation Hub for Asia-Pacific Biopharma

Recently, Morimatsu officially joined the Biologics Pharma Innovation Programme Singapore (BioPIPS). This milestone marks Morimatsu’s deep integration into the global top-tier biopharma innovation ecosystem. It will further expand the company’s capabilities in biopharmaceutical manufacturing, driv
Invitation Letter | Morimatsu Invites You to Join Us at Pharmaconex

🔔 We are pleased to announce that we will show at Pharmaconex！📅 Date: 1-3 September, 2026📍 Venue: Egypt International Exhibition Center🎯 Booth: H4.E38This is a key meeting point for professionals driving the development and industrialization of biopharmaceuticals. Our team will be on hand t
Invitation Letter | Morimatsu Invites You to Join Us at ISPE Singapore 2026

✨ We‘re thrilled to announce that we will be exhibiting at ISPE Singapore Affiliate Conference & Exhibition 2026！📅 Date: 19-21 August, 2026📍 Venue: Suntec Singapore🎯 Booth: 309🔍 We‘ll showcase our glass bioreactor and single-use systems. Come explore our latest solutions for biopharm
Key Challenges in CHO Cell Culture: Core Strategies for High-Density Culture and Scale-Up

Chinese hamster ovary (CHO) cells are widely used in biopharmaceutical manufacturing and serve as the primary production platform for more than 80% of therapeutic monoclonal antibodies. However, during process development and production-scale manufacturing, many professionals face the following chal
Bioengineering Taberis Bioreactor Series：Accelerating Bioprocess Development and Commercialization

In biopharmaceutical development and advanced life science research, an efficient, reliable, and flexible bioreactor platform is essential for accelerating process development and commercialization. Bioengineering Taberis Bioreactor Series is designed to address these needs by delivering reliable pe

Prev 1 2 3 4 5··· Next